Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124,692 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer.
Wang Y, Fu S, Zhang X, Du W, Luo L, Jiang Y, Zhou Y, Zhao Y, Yang Y, Zhao H, Fang W, Huang Y, Zhang L, Hong S. Wang Y, et al. Among authors: zhang l, zhang x. Front Immunol. 2023 May 29;14:1151385. doi: 10.3389/fimmu.2023.1151385. eCollection 2023. Front Immunol. 2023. PMID: 37313402 Free PMC article.
Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study.
Zhao S, Chen K, Shi X, Sun J, Fang W, Huang Y, Zhang L. Zhao S, et al. Among authors: zhang l. Clin Lung Cancer. 2023 Nov;24(7):e254-e258. doi: 10.1016/j.cllc.2023.06.009. Epub 2023 Jun 15. Clin Lung Cancer. 2023. PMID: 37442748 Clinical Trial.
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial.
Yang Y, Min J, Yang N, Yu Q, Cheng Y, Zhao Y, Li M, Chen H, Ren S, Zhou J, Zhuang W, Qin X, Cao L, Yu Y, Zhang J, He J, Feng J, Yu H, Zhang L, Fang W. Yang Y, et al. Among authors: zhang l, zhang j. Signal Transduct Target Ther. 2023 Aug 14;8(1):301. doi: 10.1038/s41392-023-01538-w. Signal Transduct Target Ther. 2023. PMID: 37574511 Free PMC article. Clinical Trial.
A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).
Zhao Y, Ma Y, Fan Y, Zhou J, Yang N, Yu Q, Zhuang W, Song W, Wang ZM, Li B, Xia Y, Zhao H, Zhang L. Zhao Y, et al. Among authors: zhang l. Lung Cancer. 2023 Oct;184:107355. doi: 10.1016/j.lungcan.2023.107355. Epub 2023 Aug 29. Lung Cancer. 2023. PMID: 37677918 Free article. Clinical Trial.
Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study.
Que Y, Wang J, Sun F, Wang S, Zhu J, Huang J, Zhao Z, Zhang L, Liu J, Xu J, Zhen Z, Sun X, Lu S, Zhang Y. Que Y, et al. Among authors: zhang l, zhang y. Signal Transduct Target Ther. 2023 Oct 13;8(1):392. doi: 10.1038/s41392-023-01636-9. Signal Transduct Target Ther. 2023. PMID: 37828033 Free PMC article. Clinical Trial.
Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor.
He LN, Chen T, Fu S, Jiang Y, Zhang X, Chen C, Du W, Luo L, Li A, Wang Y, Yu H, Zhou Y, Wang Y, Yang Y, Huang Y, Zhao H, Fang W, Zhang L, Hong S. He LN, et al. Among authors: zhang l, zhang x. Ther Adv Med Oncol. 2023 Oct 24;15:17588359231200463. doi: 10.1177/17588359231200463. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37881238 Free PMC article.
Impact of prophylactic dexamethasone on the efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy in patients with advanced Non-Squamous Non-Small-Cell lung cancer.
Yu H, Chen J, Zhou Y, Sheng J, Zhang X, He L, Chen L, Chu Q, Zhang L, Hong S. Yu H, et al. Among authors: zhang l, zhang x. Int Immunopharmacol. 2023 Dec;125(Pt B):111138. doi: 10.1016/j.intimp.2023.111138. Epub 2023 Nov 8. Int Immunopharmacol. 2023. PMID: 37948858 Free article.
124,692 results
You have reached the last available page of results. Please see the User Guide for more information.